dibenzothiophene sulfone | 93054-37-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: dibenzothiophene sulfone
• 英文别名: benzothiophene sulfone；2,2'-Sulfonylbis(1-benzothiophene)；2-(1-benzothiophen-2-ylsulfonyl)-1-benzothiophene
• CAS: 93054-37-6
• 化学式: C₁₆H₁₀O₂S₃
• 分子量: 330.452
• InChiKey: KXIGTQSCFXRFLP-UHFFFAOYSA-N

物化性质

• 沸点：
  568.0±25.0 °C(Predicted)
• 密度：
  1.468±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  99
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  苯并噻吩 在 叔丁基过氧化氢 作用下， 反应 6.0h， 以70%的产率得到dibenzothiophene sulfone
  参考文献：
  名称：

  The development of catalytic oxovanadium(IV)-containing microspheres for the oxidation of various organosulfur compounds

  摘要：

  The development of poly[allyiSB-co-EGDMA] beads containing a tetrad entate ligand was achieved via suspension polymerization. The catalyst poly[allylSB-co-EGDMA]-VO was synthesized by reacting (VOSO4)-O-IV with poly[allylSB-co-EGDMA]. XPS and EPR were used to confirm the presence of vanadium (V4+) on the beads. The synthesized catalyst (poly[allylSB-co-EGDMA]-VO) was found to have a BET surface area of 22 m(2) g(-1) and porosity of 135 angstrom, with the atomic force microscopy (AFM) showing more insight on the porous nature of the beads. Oxidation of thiophene (TH), benzothiophene (BT), dibenzothiophene (DBT) and 4,6-dimethyldibenzothiophene (4,6-DMDBT) was carried out using tert-butyl hydroperoxide (t-BuOOH) as oxidant. An overall conversion of 60%, 82%, 98% and 87% was achieved fot thiophene (TH), benzothiophene (BT), dibenzothiophene (DBT) and 4,6 dimethyldibenzothiophene (4,6-DMDBT) respectively at higher (t-BuOOH) to substrate ratio and at a temperature of 40 degrees C. The efficient oxidation of the various organosulfur compounds presents potential for the possible application of this catalyst in oxidative desulfurization (ODS) of crude oil. (C) 2013 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.apcata.2013.05.004

文献信息

• [EN] LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME<br/>[FR] LIGANDS DE LA PROTÉINE 2 DE TYPE LANTHIONINE C, CELLULES PRÉPARÉES AVEC CEUX-CI, ET THÉRAPIES LES UTILISANT
  申请人：LANDOS BIOPHARMA INC

  公开号：WO2021127472A1

  公开（公告）日：2021-06-24

  Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including autoimmune diseases, inflammatory diseases, chronic inflammatory diseases, diabetes, and infectious diseases, such as lupus, rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, viral diseases, and nonalcoholic steatohepatitis. The compounds can also be used to generate cells, such as immune cells, for treating the conditions.

  提供的是靶向兰硫氨酸合成酶C样蛋白2途径的化合物。这些化合物可用于治疗多种疾病，包括自身免疫性疾病、炎症性疾病、慢性炎症性疾病、糖尿病和传染性疾病，如狼疮、类风湿性关节炎、1型糖尿病、炎症性肠病、病毒性疾病和非酒精性脂肪肝炎。这些化合物还可用于生成细胞，如免疫细胞，以治疗这些疾病。
• [EN] PLXDC2 LIGANDS<br/>[FR] LIGANDS DE PLXDC2
  申请人：LANDOS BIOPHARMA INC

  公开号：WO2021195360A1

  公开（公告）日：2021-09-30

  Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.

  提供了针对含有plexin结构域2（PLXDC2）的化合物。这些化合物可以用于治疗炎症或免疫介导性疾病、糖尿病、传染病和癌症等疾病。这些化合物可以用于治疗系统性红斑狼疮、类风湿关节炎、多发性硬化症、自身免疫性脑炎、糖尿病肾病、糖尿病视网膜病变、银屑病和炎症性肠病等特定疾病。
• AZAINDOLE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY
  申请人：Shionogi Co., Ltd.

  公开号：EP1911759A1

  公开（公告）日：2008-04-16

  The present invention creates an azaindole derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further providing a therapeutic agent for treating allergic diseases. A compound of the general formula (I) wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a 3- to 8-membered nitrogen-containing non-aromatic heterocyclic ring etc.; the formula of -X1=X2-X3=X4- is a formula of -C(R1)=C(R2)-C(R3)=N- etc.; R1, R2, R3, R4 and R5 are independently a hydrogen atom or a halogen atom etc.; R6 is optionally substituted C1-C6 alkyloxy etc.; R7 is independently a halogen atom etc.; R8 is optionally substituted C1-C6 alky etc.; R9 is carboxy etc.; M is sulfonyl etc.; Y is a single bond etc.; L1, L2 and L3 are a single bond or alkylene optionally containing one or two heteroatoms etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or hydrate thereof.

  本发明创造了一种具有 DP 受体拮抗活性的氮杂环吲哚衍生物和一种包含上述化合物作为活性成分的药物组合物，并进一步提供了一种治疗过敏性疾病的治疗剂。 通式（I）的化合物 其中环 A 是芳香碳环等；环 B 是 3 至 8 元含氮非芳香杂环等；式中 -X1=X2-X3=X4- 是 -C(R1)=C(R2)-C(R3)=N- 等；R1、R2、R3、R4 和 R5 独立地是氢原子或卤原子等；R6 是任选取代的 C1-C6 烷氧基等。R7独立地为卤原子等；R8为任选取代的C1-C6烷基等；R9为羧基等；M为磺酰基等；Y为单键等；L1、L2和L3为单键或任选含有一个或两个杂原子的亚烷基等；n为0等；q为0等；其药学上可接受的盐或水合物。
• INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY
  申请人：Shionogi Co., Ltd.

  公开号：EP1932839A1

  公开（公告）日：2008-06-18

  The present invention provides an indolecarboxylic acid derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A compound of the general formula (I): wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a nitrogen-containing non-aromatic heterocyclic ring etc.; the formula of -X1=X2-X3=X4- is a formula of -C(R1)=C(R2)-C(R3)=C(R4)- etc.; X5 is C(R5) or N; R1, R2, R3, R4 and R5 is independently a hydrogen atom, a halogen atom etc; R6 is a formula of -Z-R10 etc. wherein Z is alkylene etc., and R10 is carboxy etc.; R7 is optionally substituted alkyloxy etc.; R8 is independently a halogen atom etc.; R9 is independently optionally substituted alkyl etc.; Y is a single bond etc.; n is 0 etc.; q is 0 etc.; a pharmaceutically acceptable salt or a solvate thereof.

  本发明提供了一种具有DP受体拮抗活性的吲哚羧酸衍生物和一种包含上述化合物作为活性成分的药物组合物，并进一步提供了一种治疗过敏性疾病的治疗剂。 通式(I)的化合物： 其中环 A 是芳香碳环等；环 B 是含氮非芳香杂环等；式中 -X1=X2-X3=X4- 是 -C(R1)=C(R2)-C(R3)=C(R4)- 等；X5 是 C(R5) 或 N；R1、R2、R3、R4 和 R5 独立地是氢原子、卤素原子等；R6 是式中 -Z-R10 等，其中 Z 是亚烷基等、R7 是任选取代的烷氧基等；R8 独立地是卤素原子等；R9 独立地是任选取代的烷基等；Y 是单键等；n 是 0 等；q 是 0 等； 药学上可接受的盐或其溶液。
• SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY
  申请人：Shionogi&Co., Ltd.

  公开号：EP1939175A1

  公开（公告）日：2008-07-02

  The present invention provides an sulfonamide derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. A compound of the general formula (II): wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a nitrogen-containing non-aromatic heterocyclic ring etc.; the ring C is an aromatic carbocyclic ring etc.; R1 is carboxy etc.; R2 is independently a halogen atom etc.; R3 is optionally substituted alkyloxy etc.; R4 is independently a halogen atom etc.; R5 is independently optionally substituted alkyl etc.; M is sulfonyl etc.; Y is a single bond etc.; L1 is a single bond etc.; L2 is a single bond etc.; k is 0, 1, 2, 3 or 4; n is 0, 1 or 2; and q is 0, 1, 2 or 3; provided that a) k is not 0 when the ring B is a 6-membered nitrogen-containing heterocyclic ring containing one or two nitrogen atom(s) and the ring C is a benzene ring, etc.; a pharmaceutically acceptable salt or a hydrate thereof.

  本发明提供了一种具有DP受体拮抗活性的磺酰胺衍生物和一种包含上述化合物作为活性成分的药物组合物，并进一步提供了一种治疗过敏性疾病的治疗剂。 通式(II)的化合物： 其中环 A 是芳香碳环等；环 B 是含氮非芳香杂环等；环 C 是芳香碳环等；R1 是羧基等；R2 独立地是卤素原子等；R3 是任选取代的烷氧基等；R4 独立地是卤素原子等；R5 独立地是任选取代的烷基等；M 是磺酰基等。M是磺酰基等；Y是单键等；L1是单键等；L2是单键等；k是0、1、2、3或4；n是0、1或2；q是0、1、2或3；条件是 a) 当环 B 是含有一个或两个氮原子的 6 元含氮杂环且环 C 是苯环等时，k 不是 0； 药学上可接受的盐或其水合物。